Inflammation in central nervous system injury

Stuart M Allan, Nancy J Rothwell, Stuart M Allan, Nancy J Rothwell

Abstract

Inflammation is a key component of host defence responses to peripheral inflammation and injury, but it is now also recognized as a major contributor to diverse, acute and chronic central nervous system (CNS) disorders. Expression of inflammatory mediators including complement, adhesion molecules, cyclooxygenase enzymes and their products and cytokines is increased in experimental and clinical neurodegenerative disease, and intervention studies in experimental animals suggest that several of these factors contribute directly to neuronal injury. Most notably, specific cytokines, such as interleukin-1 (IL-1), have been implicated heavily in acute neurodegeneration, such as stroke and head injury. In spite of their diverse presentation, common inflammatory mechanisms may contribute to many neurodegenerative disorders and in some (e.g. multiple sclerosis) inflammatory modulators are in clinical use. Inflammation may have beneficial as well as detrimental actions in the CNS, particularly in repair and recovery. Nevertheless, several anti-inflammatory targets have been identified as putative treatments for CNS disorders, initially in acute conditions, but which may also be appropriate to chronic neurodegenerative conditions.

References

    1. Curr Opin Neurobiol. 1995 Oct;5(5):636-41
    1. Mol Med. 1995 Nov;1(7):732-43
    1. Ann Neurol. 1996 May;39(5):618-24
    1. J Cereb Blood Flow Metab. 1997 Apr;17(4):370-5
    1. J Lipid Mediat Cell Signal. 1997 Jul;16(3):199-208
    1. Neurosci Lett. 1997 Jul 18;230(2):109-12
    1. J Neurosci. 1997 Dec 1;17(23):9157-64
    1. Eur Cytokine Netw. 1997 Dec;8(4):345-9
    1. Stroke. 1998 Feb;29(2):529-34
    1. J Immunol. 1998 Aug 15;161(4):1989-96
    1. J Cereb Blood Flow Metab. 1999 Oct;19(10):1099-108
    1. J Neurosurg. 2000 Jan;92(1):108-20
    1. Brain Pathol. 2000 Jan;10(1):95-112
    1. Ann Neurol. 2000 May;47(5):571-4
    1. Brain. 2000 Jun;123 ( Pt 6):1174-83
    1. Stroke. 2000 Jul;31(7):1715-20
    1. Immunopharmacology. 2000 Aug;49(1-2):171-86
    1. Neuropsychol Rev. 2000 Jun;10(2):115-29
    1. Eur J Neurosci. 2000 Jul;12(7):2265-72
    1. J Neurosci. 2000 Nov 1;20(21):8153-9
    1. Trends Neurosci. 2000 Dec;23(12):618-25
    1. Arch Immunol Ther Exp (Warsz). 2000;48(5):389-98
    1. Eur J Pharmacol. 2001 Feb 9;413(1):11-29
    1. Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1294-9
    1. Ann Neurol. 2001 Mar;49(3):281-4
    1. Physiol Rev. 2001 Apr;81(2):871-927
    1. J Cereb Blood Flow Metab. 2001 Mar;21(3):218-25
    1. Brain Res Bull. 2001 Mar 1;54(4):329-38
    1. Semin Arthritis Rheum. 2001 Apr;30(5 Suppl 2):17-20
    1. Cytokine. 2001 Jun 7;14(5):272-82
    1. J Immunol. 2001 Aug 1;167(3):1821-9
    1. J Neurosci. 2001 Aug 1;21(15):5528-34
    1. Microsc Res Tech. 2001 Jul 1;54(1):47-58
    1. J Neurol Neurosurg Psychiatry. 2001 Oct;71(4):448-54
    1. Physiol Behav. 2001 Aug;73(5):873-86
    1. Nat Rev Neurosci. 2001 Oct;2(10):734-44
    1. Clin Microbiol Rev. 2001 Oct;14(4):810-20, table of contents
    1. Arch Neurol. 2001 Nov;58(11):1790-2
    1. Cytokine Growth Factor Rev. 2002 Aug-Oct;13(4-5):323-40
    1. Muscle Nerve. 2002 Oct;26(4):459-70
    1. Glia. 2002 Nov;40(2):133-9
    1. Glia. 2002 Nov;40(2):140-55
    1. Glia. 2002 Nov;40(2):240-51
    1. J Neurol Sci. 2002 Nov 15;203-204:29-34
    1. J Alzheimers Dis. 2002 Oct;4(5):435-45
    1. J Cereb Blood Flow Metab. 2002 Dec;22(12):1399-419
    1. J Neurovirol. 2002 Dec;8(6):529-38
    1. Prog Neurobiol. 2002 Dec;68(5):311-23
    1. Nat Rev Neurosci. 2003 Feb;4(2):103-12
    1. J Cereb Blood Flow Metab. 2003 Feb;23(2):137-49
    1. Stroke. 2003 Feb;34(2):330-2
    1. Stroke. 2003 Feb;34(2):359-61
    1. J Neural Transm Suppl. 2002;(63):91-109
    1. J Neurosci. 2003 Mar 1;23(5):1605-11
    1. Neurosci Res. 2003 Mar;45(3):313-24
    1. Sports Med. 1987 May-Jun;4(3):194-210
    1. J Clin Invest. 1990 Sep;86(3):981-5
    1. J Clin Invest. 1991 Apr;87(4):1360-6
    1. J Neuroimmunol. 1992 Jul;39(1-2):11-21
    1. J Immunol. 1993 Aug 15;151(4):2132-41
    1. J Leukoc Biol. 1994 Sep;56(3):407-15
    1. Ann Neurol. 1995 Jan;37(1):82-8
    1. J Neuroimmunol. 1994 Dec;55(2):153-60
    1. FASEB J. 1995 Dec;9(15):1577-84
    1. Prog Neurobiol. 1998 Oct;56(1):19-35
    1. J Cereb Blood Flow Metab. 1998 Dec;18(12):1283-7
    1. Res Immunol. 1998 Sep-Oct;149(7-8):721-5
    1. J Infect Dis. 1999 Mar;179 Suppl 2:S294-304
    1. Toxicol Pathol. 1999 Jan-Feb;27(1):111-4
    1. J Neurosci. 1999 Jun 15;19(12):5054-65
    1. Brain Res Brain Res Rev. 1999 Jul;30(1):77-105
    1. Eur J Pharmacol. 1999 Jun 30;375(1-3):41-50
    1. J Neurosci. 2002 Jan 1;22(1):38-43
    1. Neurobiol Aging. 2001 Nov-Dec;22(6):811-7
    1. Neurobiol Aging. 2002 Jan-Feb;23(1):59-64
    1. Eur J Neurol. 2001 Nov;8(6):707-10
    1. Histol Histopathol. 2002 Jan;17(1):273-88
    1. Arch Neurol. 2002 Mar;59(3):391-7
    1. Microbes Infect. 2002 Mar;4(3):291-300
    1. Nat Rev Neurosci. 2002 Mar;3(3):216-27
    1. Expert Opin Investig Drugs. 2002 May;11(5):603-14
    1. J Neurotrauma. 2002 May;19(5):503-57
    1. Neurosci Lett. 2002 Jun 21;326(1):67-9
    1. Neurosci Lett. 2002 Jun 21;326(1):70-2
    1. Immunol Rev. 2001 Dec;184:117-28
    1. J Neurosci Res. 2002 Jun 15;68(6):647-54
    1. J Neurosci. 2002 Jul 15;22(14):5910-9
    1. J Leukoc Biol. 2002 Aug;72(2):233-8
    1. Med Sci Monit. 2002 Aug;8(8):RA165-77
    1. Neuron. 2002 Aug 1;35(3):419-32

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit